How Psilodex is built.
What each record contains, what the codes mean, where the information comes from, and how it is kept current.
01 Scope
Psilocybin from mushrooms (not synthetic), provided in a state-regulated program in Colorado, Oregon or New Mexico. For each of 700 medications, supplements and substances: what is known about it with psilocybin, and what each state's rules say.
Made by Psilodex LLC, whose owner is a Colorado-licensed natural medicine facilitator. Disclosure.
Not medical advice, a screening decision, or clearance to participate. It does not rate a medication, recommend a change, or say whether someone can take part. Psilodex presents information only. Do not stop or change a medication without talking with the prescriber.
02 What a record contains
Every record, same order03 Evidence codes
A record can carry more than one| Code | Meaning | Used in |
|---|---|---|
| RCT | Controlled trial | 6 records |
| OL | Open-label trial | 8 records |
| CR | Case reports or online surveys | 16 records |
| XP | Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text | 23 records |
| ND | No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts | 661 records |
Most records rest on the medication’s own pharmacology and label, because few medications have been studied with psilocybin. A code describes the kind of evidence, not how safe a combination is.
04 Label contraindications
Clinical data and state rules are separate factsRecords do not carry a separate contraindication line. Where a medication’s own label states that use with a drug class that includes psilocybin is contraindicated (2 records), the interaction text says so and cites the label. Other label cautions appear as pharmacology properties and in the text. The absence of such a label statement is not a finding that a combination is without risk.
05 State rule statuses
| Named | A provision names this medication or its class. |
| Not named | No provision names this medication or its class. |
| Unsettled | Whether a provision applies to this medication is unsettled. |
| Pending | Rules are not final; no provision naming this medication has been found. |
Rule text is checked against the official source; each record shows when its state rules were last checked.
06 Pharmacology relevant to psilocybin
20 properties- Serotonergic
- Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker.
- MAO inhibition
- Inhibits monoamine oxidase, the enzyme that breaks down serotonin and other monoamines. MAO may also help clear psilocin (lab studies disagree on how much), so it could change how strong and how long the psilocybin effect is, and it raises serotonin levels.
- Blocks 5-HT2A (may blunt effects)
- Blocks the 5-HT2A receptor, the main receptor psilocybin acts through. Can reduce or block the psilocybin effect.
- QT-prolonging
- Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium.
- Raises blood pressure or heart rate
- Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add.
- Lowers blood pressure or causes orthostasis
- Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting.
- Lowers seizure threshold or carries seizure risk
- Makes a seizure more likely, or has been linked to seizures.
- Withdrawal or rebound if stopped abruptly
- Stopping suddenly can cause withdrawal or a rebound of symptoms.
- Anticholinergic
- Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination.
- Sedating or CNS depressant
- Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances.
- UGT inhibition (theoretical effect on psilocin levels)
- Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect.
- Slows gastric emptying
- Slows how quickly the stomach empties. Can delay or change the onset of a dose taken by mouth and add to nausea.
- Hypoglycemia risk
- Can cause low blood sugar, especially if meals are missed or delayed.
- Dehydration or electrolyte risk
- Can cause dehydration or shifts in sodium or potassium.
- Dissociative (NMDA antagonist)
- Blocks NMDA receptors and can cause dissociation: feeling detached from the body or surroundings. Effects can add to psilocybin’s.
- Psychiatric reactions
- The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening.
- Opioid
- Activates opioid receptors, causing pain relief, sedation and slowed breathing at higher doses. Psilocybin does not slow breathing. Stopping an opioid suddenly can cause withdrawal.
- Opioid blocker
- Blocks opioid receptors. It can trigger sudden withdrawal in someone taking opioids, and after it wears off, a usual opioid dose can cause overdose.
- Speeds up drug metabolism
- Increases the liver enzymes that break down many medicines, lowering their levels. When it is stopped, levels of other medicines can rise over the following weeks.
- Liver injury
- The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin.
Each property on a record is supported by a cited source that states it. On the report, properties are counted across the whole list (for example, “Serotonergic · 2 / 4”) so overlaps are visible. A count is not a score. Seizures that can follow stopping a medication are listed under withdrawal, not seizure threshold.
07 Citation standard
Every record carries at least one public citation, and every pharmacology property is supported by a source that states it: a product label, a reference textbook page, a peer-reviewed paper or a government page. “Not studied with psilocybin” means no study or report combining it with psilocybin was found; those records cite the systematic reviews of psychedelic drug interactions for that absence. The data does not build if any record or property lacks a source. All sources →
08 Review and updates
Scheduled checks look for new product labels, state rule changes and new papers. Findings go to a review queue, never straight into the data.
Each change is checked against the source it cites before it is accepted. Nothing is added from memory or opinion.
The data is validated before release: every record needs a citation and every pharmacology property a source.
A new dated version is published with a plain-language changelog. Reports name the version they used.
09 Limits
- Most interaction evidence is thin: case reports, surveys, mechanism, or data from LSD rather than psilocybin.
- Doses, timing, other medications and health conditions change how any combination plays out. A record cannot account for them.
- A medication missing from the database is not evidence of no interaction.
- Rule summaries help find the right provision; the official rule text governs.
10 Report an error or a missing medication
Tell us what's wrong and, if you can, the source. Please don't include anything about yourself or anyone else's health. Accepted fixes appear in the changelog.